Australia's conditional approval of COVID-19 treatment unlikely to help Celltrion rebound
Samples of Celltrion's COVID-19 antibody treatment Regkirona / Courtesy of CelltrionBy Kim Jae-heunAustralia's Therapeutic Goods Administration (TGA) said Tuesday it has conditionally approved Celltrion's COVID-19 antibody treatment Regkirona for use in the country. Many shareholders of the Korean biopharmaceutical company expected the announcement to lift its stock price, but it seems to have had no effect. Celltrion stocks to a plunge from 291,000 won on Sept. 23 to 193,500 won on Nov. 8. On Tuesday, despite the approval notice, Celltrion stocks fell by 1.45 percent to finish at 203,500 won on the KOSPI, according to data by the bourse operator Korea Exchange (KRX). Earlier, approval of Regkirona's distribution in Europe failed to help Celltrion's stock price. Europe, along with Australia, was considered a region that will help the local biopharmaceutical company to improve its value.This year has been tough for Celltrion as the overall industry has been on a losing streak. The company announced its plan recently to develop a customized inhaled medication for the Omicron variant, b
Dec 7, 2021By Kim Jae-heun